Acromegaly Pipeline

DelveInsight’s, “Acromegaly- Pipeline Insight, 2025,”report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Acromegaly pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Acromegaly Understanding

Acromegaly: Overview

Acromegaly is a rare endocrine disorder caused by a benign tumor of pituitary gland that results in over-secretion of growth hormone (GH.) that in turn causes abnormal increase in insulin-like growth factor-1 (IGF-1). Most pituitary adenomas are slow growing and benign. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth, and sleep apnea.  In adults, too much of this hormone causes bones, cartilage, body organs, and other tissues to increase in size. Common changes in appearance include enlarged or swollen nose, ears, hands, and feet and jaw. The medical complications include cardiovascular disease like hypertension, cardiomyopathy, and diabetes mellitus etc.

 

 Because acromegaly progresses slowly, early signs may not be obvious for years. Sometimes, people notice the physical changes only by comparing old photos with newer ones. Overall, acromegaly signs and symptoms tend to vary from one person to another and may include any of the following: enlarged hands and feet, enlarged facial features, including the facial bones, lips, nose, and tongue, coarse, oily, thickened skin, excessive sweating, and body odor. Acromegaly is a rare disorder caused by excess levels of growth hormone (GH) in the body. In most patients, excess levels of GH are caused by a benign (noncancerous) tumor in the pituitary gland (pituitary adenoma). Most adenomas form from the excessive growth of a pituitary cell called a somatotrope cell (the pituitary cell that normally secretes GH). In most patients, the disease is sporadic and not due to an inherited genetic mutation.

The disease can be diagnosed by measuring IGF-1 levels in blood the elevated IGF-1 level suggests acromegaly second method is by growth hormone suppression test it is the best method to diagnose acromegaly and lastly imaging by doing MRI to help identify the location and size of a tumor in pituitary gland.

 

Treatment options depends on the location and size of tumor, the severity of symptoms, and age and overall health of the person.  It includes surgery options, medications as well as radiation treatments. The medication options developed for the treatment of acromegaly generally focus on drugs that reduce growth hormone production (somatostatin analogues) somatostatin works against (inhibits) GH production like octreotide (Sandostatin) and lanreotide (Somatuline Depot), drugs that lower hormone levels (dopamine agonists) like cabergoline and bromocriptine (Parlodel) that may help lower levels of GH and IGF-1 and also drugs to block the action of GH (growth hormone antagonist).

 

"Acromegaly- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acromegaly pipeline landscape is provided which includes the disease overview and Acromegaly treatment guidelines. The assessment part of the report embraces, in depth Acromegaly commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acromegaly collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Acromegaly R&D. The therapies under development are focused on novel approaches to treat/improve Acromegaly.

 

Acromegaly Emerging Drugs Chapters

This segment of the Acromegaly report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Acromegaly Emerging Drugs

• Paltusotine: Crinetics Pharmaceuticals Inc.

Paltusotine is a first oral, once-daily, selectively targeted somatostatin receptor type 2 (SST2) agonist developed for the treatment of acromegaly. It was designed by the Crinetics to provide a convenient once-daily option for people living with acromegaly. Paltusotine, an investigational drug for acromegaly, has received FDA acceptance of its New Drug Application (NDA). The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of September 25, 2025, for the NDA review. Currently it is in Registration stage of clinical trial evaluation to treat Acromegaly. The drug maintained the IGF-1 levels in acromegaly patients in both Phase II and in recent Phase III studies.

 

• Atesidorsen: Percheron Therapeutics

Atesidorsen (formerly ATL1103) is a second-generation antisense oligonucleotide developed by Percheron Therapeutics for the treatment of acromegaly, a hormonal disorder characterized by excess growth hormone and elevated IGF-1 levels. The therapy works by inhibiting the human growth hormone receptor (GHr), thereby reducing IGF-1 production. Atesidorsen showed promising results in a Phase II clinical trial, demonstrating its potential to normalize IGF-1 levels in patients. However, in April 2025, Percheron Therapeutics announced the discontinuation of atesidorsen’s development, citing limited commercial viability under current development pathways. Currently the drug is in Phase II stage of its development for the treatment of Acromegaly.

 

• TE 8214: Immunwork

TE‑8214 is a next‑generation somatostatin receptor agonist designed by Immunwork (T‑E Pharma Holding) for the treatment of acromegaly and neuroendocrine tumors. Its highly water‑soluble, fatty‑acid‑conjugated peptide formulation enables subcutaneous administration with a fine 30‑gauge needle, virtually eliminating injection‑site pain and nodules seen with current therapies. In the Phase I single‑ascending dose trial (completed late 2024), TE‑8214 was exceptionally well tolerated: in the highest dose groups, about 83 % of participants achieved >20 % reduction in IGF‑1, with minimal gastrointestinal side‑effects. Based on this strong safety and pharmacodynamic profile, Immunwork plans to initiate Phase II trials in Taiwan in Q3 2025 and is actively seeking strategic partnerships to support global development. Currently the drug is in Phase I stage of its development for the treatment of Acromegaly.

Further product details are provided in the report……..

 

Acromegaly: Therapeutic Assessment

This segment of the report provides insights about the different Acromegaly drugs segregated based on following parameters that define the scope of the report, such as:

• Major  Players in Acromegaly

There are approx. 10+ key companies which are developing the therapies for Acromegaly. The companies which have their Acromegaly drug candidates in the most advanced stage, i.e. phase III include, Crinetics Pharmaceuticals Inc.

 

Phases

Delve Insight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase II)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Acromegaly pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

 

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Acromegaly: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acromegaly therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acromegaly drugs

Acromegaly Report Insights

• Acromegaly Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Acromegaly Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acromegaly drugs?
• How many Acromegaly drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acromegaly?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acromegaly therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acromegaly and their status?
• What are the key designations that have been granted to the emerging drugs?